Onesource Specialty Pharma vs Nifty 50: Returns Compared
- September 2, 2026
- Posted by: Kunal Singla
- Category: Market
Onesource Specialty Pharma share price Rs 1,527.90 on NSE. Onesource Specialty Pharma vs Nifty 50 over 1 year: -18.73% vs -2.41%. 52-week high Rs 1,921.90, low Rs 1,057.00.
Quick Answer
Onesource Specialty Pharma vs Nifty 50 shows Onesource Specialty Pharma trailing the benchmark on a one-year view, with a return of -18.73% against the Nifty 50’s -2.41%. With only a short listing history, longer-term comparisons against the Nifty 50 are not yet meaningful for this stock. Investors comparing the two should also weigh Onesource Specialty Pharma’s trading liquidity, valuation and sector context rather than relying on returns alone.
Onesource Specialty Pharma vs Nifty 50 is a comparison that looks different depending on the time frame chosen. Onesource Specialty Pharma trades on the NSE under the symbol ONESOURCE, and its 1M return of -2.09% compares with the Nifty 50’s -1.44% over the same period.
The Onesource Specialty Pharma vs Nifty 50 comparison matters because Onesource Specialty Pharma is a single stock exposed to its own sector and company-specific developments, while the Nifty 50 spreads risk across 50 large companies. This article lines up Onesource Specialty Pharma share price performance against the Nifty 50 across 1 month, 3 months, 6 months, 1 year, using NSE closing data.
Click Here – Get Free Investment Predictions
Onesource Specialty Pharma vs Nifty 50: Performance at a Glance
The table below sets out Onesource Specialty Pharma vs Nifty 50 performance across the available time frames, measured from NSE closing prices up to 1 September 2026.
| Time Frame | Onesource Specialty Pharma Return | Nifty 50 Return | Difference |
|---|---|---|---|
| 1 Month | -2.09% | -1.44% | -0.65% pp |
| 3 Months | -16.44% | +2.78% | -19.22% pp |
| 6 Months | +16.68% | -3.35% | +20.03% pp |
| 1 Year | -18.73% (Onesource Specialty Pharma) | -2.41% (Nifty 50) | -16.32% pp |
On the Onesource Specialty Pharma vs Nifty 50 scorecard, Onesource Specialty Pharma has lagged the index over the most recent one-year window. With only a short listing history, longer-term comparisons against the Nifty 50 are not yet meaningful for this stock.
Check the Univest Screener for live Onesource Specialty Pharma and Nifty 50 data
Why the Onesource Specialty Pharma vs Nifty 50 Gap Exists
Onesource Specialty Pharma’s stock can move quite differently from the Nifty 50 because it carries concentrated exposure to its own sector and business cycle, unlike the index which blends 50 companies across banking, IT, energy and consumer sectors. This is the main driver of the gap seen in the Onesource Specialty Pharma vs Nifty 50 return table above.
A second factor behind the Onesource Specialty Pharma vs Nifty 50 divergence is valuation and trading liquidity. Company-specific news, quarterly results and sector sentiment can move Onesource Specialty Pharma’s price sharply in either direction over short periods, while the Nifty 50’s return reflects the blended earnings trajectory of its constituents and is far less exposed to any single stock’s swings.
Download the Univest iOS App or Univest Android App to track Onesource Specialty Pharma and Nifty 50 live on the go.
Onesource Specialty Pharma vs Nifty 50: Has Onesource Specialty Pharma Beaten the Benchmark?
Onesource Specialty Pharma has not kept pace with the Nifty 50 over the past year, posting a return of -18.73% against the index’s -2.41% over the same period.
Risks of the Onesource Specialty Pharma vs Nifty 50 Comparison
Reading too much into a Onesource Specialty Pharma vs Nifty 50 comparison has real limitations that investors should weigh before drawing conclusions. Onesource Specialty Pharma carries concentrated business and sector risk that a diversified index does not, and its trading volumes and price swings can differ meaningfully from the Nifty 50’s more liquid, blended profile. A stock’s 52-week range of Rs 1,057.00 to Rs 1,921.90 also shows the kind of volatility that a single-stock investment carries relative to a broad index.
Conclusion
Onesource Specialty Pharma vs Nifty 50 highlights how a single stock’s return path can differ from a diversified benchmark over different time horizons. Investors weighing the Onesource Specialty Pharma vs Nifty 50 record should factor in Onesource Specialty Pharma’s volatility, liquidity and sector concentration alongside its return history, and consult a SEBI-registered advisor before making an allocation decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Has Onesource Specialty Pharma outperformed the Nifty 50 in the last year?
Ans. No. Onesource Specialty Pharma returned -18.73% over the past year while the Nifty 50 returned -2.41% over the same period, based on NSE closing prices to 1 September 2026.
What is the Onesource Specialty Pharma share price today compared to Nifty 50?
Ans. Onesource Specialty Pharma share price stood at Rs 1,527.90 on NSE, while the Nifty 50 traded at 24,031.60 based on the same closing data window.
What is the 52-week high and low of Onesource Specialty Pharma?
Ans. Onesource Specialty Pharma’s 52-week high is Rs 1,921.90 and its 52-week low is Rs 1,057.00, based on NSE data.
Why does Onesource Specialty Pharma show bigger price swings than the Nifty 50?
Ans. Onesource Specialty Pharma carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies, so company-specific news moves Onesource Specialty Pharma’s price more sharply than the diversified index, a key reason the Onesource Specialty Pharma vs Nifty 50 return gap varies across time frames.
Is Onesource Specialty Pharma a good long-term investment compared to a Nifty 50 index fund?
Ans. Onesource Specialty Pharma’s suitability depends on an investor’s risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund; long-term investors should weigh the Onesource Specialty Pharma vs Nifty 50 return history alongside the company’s fundamentals and consult a SEBI-registered advisor.
